Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 0.50 |
| ▸ | DRD5 | P21918 | 11/20 | 0.50 |
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | DRD3 | P35462 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384325 | 0.93 | MAOA (0.50) | DRD1DRD5DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL31195438 | 0.91 | MAOA (0.52) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL12759201 | 0.83 | CA2 (0.43) | — | |
| SCHEMBL13356016 | 0.83 | CA1 (0.34) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL4027923 | 0.79 | ADRA2A (0.42) | — | |
| SCHEMBL29956883 | 0.79 | ALDH1A1 (0.45) | — | |
| SCHEMBL442154 | 0.79 | ALDH1A1 (0.45) | — | |
| SCHEMBL8400882 | 0.78 | NOTUM (0.40) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL17677162 | 0.76 | HRH3 (0.47) | DRD1DRD2DRD3 | |
| SCHEMBL2559623 | 0.74 | ESR2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7704994-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7696193-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| EP-0612741-B1 | Cyclic derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-06-10 | — | — | EP | disclosed |
| EP-0612741-A1 | Cyclic derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | DRD1 187/4885DRD5 178/4885DRD2 75/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | DRD1 84/4885DRD5 214/4885DRD2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.